Proximagen Group plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Proximagen Group plc
User fee goal date calendar for June includes AMAG’s female sexual dysfunction drug Vyleesi, new indications for Sanofi/Regeneron’s Dupixent in rhinosinusitis and Merck’s Zerbaxa in nosocomial pneumonia.
The latest drug development news and highlights from our US FDA Performance Tracker.
Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Cambridge Biotechnology Ltd (CBT)
- Minster Pharmaceuticals